NewsFeed
Headlines ASRM ESHRE FIGO ACOG Fertility and Sterility PCOS
August, 2026
August 2026
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  
Vipin Chandra: L-Leucine in Controlled Ovarian Hyperstimulation
Vipin Chandra/LinkedIn
Dec 26, 2025, 12:28

Vipin Chandra: L-Leucine in Controlled Ovarian Hyperstimulation

Vipin Chandra, Director of Matcare Maternity, shared a post on LinkedIn:

“L-Leucine in Controlled Ovarian Hyperstimulation (COH):
A Metabolic Adjuvant Worth Serious Clinical Attention

Poor ovarian response remains one of the most frustrating challenges in ART. Despite protocol refinement and gonadotropin escalation, outcomes often plateau—especially in women with diminished ovarian reserve (DOR) and hypo-responsive follicles.

Increasingly, attention is shifting upstream—from hormones alone to the intracellular metabolic pathways that govern follicular competence.

One nutrient drawing justified mechanistic interest is L-Leucine.

Why L-Leucine Matters Biologically

L-Leucine is a branched-chain amino acid and the most potent physiological activator of the mTOR pathway, a central regulator of:

  • granulosa cell proliferation
  • protein synthesis
  • mitochondrial function
  • steroidogenesis
  • follicular growth and survival

mTOR signaling is now well established as essential for follicular activation and oocyte competence.

Adhikari et al., PNAS 2010

Mechanistic Advantage in Low-Reserve Ovaries

Unlike insulin-dependent activators, L-Leucine directly activates mTORC1 via Rag-GTPase signaling, supporting cellular metabolism even under stress conditions—precisely the environment seen in aging or hypo-responsive ovaries.

Wolfson et al., Science 2016

Granulosa cells are highly amino-acid sensitive, and preclinical work shows leucine improves:

  • mitochondrial activity
  • steroidogenic capacity
  • granulosa cell survival

Zhang et al., Biology of Reproduction 2017

What Clinical Data Suggest So Far

While IVF-specific RCTs isolating L-Leucine are limited, human nutritional and metabolic studies consistently suggest that optimizing amino-acid–mTOR signaling improves ovarian responsiveness.

L-Leucine has also been studied as part of multi-nutrient metabolic strategies, commonly combined with:

  • myo-inositol (FSH/insulin signaling, oxidative stress reduction)
  • selenium (steroidogenesis, antioxidant support)

Genazzani et al., Gynecological Endocrinology 2018
Palomba et al., Human Reproduction Update 2021

Clinical Interpretation (Balanced, Not Hype)

At present, L-Leucine should be viewed as a metabolic adjuvant—not a standalone solution.

Its potential role appears strongest in:

  • DOR / POSEIDON low-prognosis patients
  • hypo-responsive granulosa cell environments
  • aging ovaries with metabolic stress

When combined thoughtfully with agents like myo-inositol and selenium, L-Leucine may offer dual-pathway support:
mTOR activation + insulin/FSH signaling optimization

What is urgently needed:

  • well-designed RCTs isolating L-Leucine
  • follicular-fluid and granulosa-cell human studies
  • POSEIDON-stratified outcome analysis.”

Vipin Chandra: L-Leucine in Controlled Ovarian Hyperstimulation

Stay updated on all scientific advances in the field of fertility with Fertility News.

NewsFeed